title: [A change in adrenal responsiveness in sotalol-treated patients with paroxysmal atrial fibrillation depending on autonomic nervous system tone].
abstract: OBJECTIVE
  To evaluate the efficacy of sotalol depending on the magnitude of changes in adrenal responsiveness and autonomic nervous system tone in patients with paroxysmal atrial fibrillation (AF).
  
  
  METHODS
  Twenty-six patients with paroxysmal AF in the presence of coronary heart disease (CHD) and hypertension were examined. Sinus rhythm variability and sympathicotonic and vagotonic disorders were studied in patients with paroxysmal AF before and during sotalol treatment. A commercial Beta-ARM-Agat kit was used to estimate the adrenal responsiveness of erythrocyte membranes (β-APM), which can judge the body's individual sensitivity to β-adrenoblockers.
  
  
  RESULTS
  Sotalol used in the average therapeutic doses of 160-240 mg did not reduce ejection fraction or increase atrioventricular conduction up to abnormal values. In patients with borderline and mild hypertension, the drug lowered blood pressure statistically significantly (p=0.01) and was well tolerated. The drug increased the sensitivity of β-adrenoblockers in patients with adrenergic AF.
  
  
  CONCLUSIONS
  The effect of sotalol on the autonomic nervous system manifested in the higher power of a high-frequency spectral component of heart rate variability than in that of a low-frequency one. Long-term sotalol administration significantly reduced β-APM, increasing the sensitivity of adrenoceptors.
authors.affiliation: Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia.
authors.forename: E V
authors.initials: EV
authors.lastname: Borisova
authors.affiliation: Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia.
authors.forename: S A
authors.initials: SA
authors.lastname: Afanasyev
authors.affiliation: Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia.
authors.forename: T Yu
authors.initials: TY
authors.lastname: Rebrova
authors.affiliation: Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia.
authors.forename: I V
authors.initials: IV
authors.lastname: Kisteneva
authors.affiliation: Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia.
authors.forename: R E
authors.initials: RE
authors.lastname: Batalov
authors.affiliation: Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia.
authors.forename: S V
authors.initials: SV
authors.lastname: Popov
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics; D000368:Aged; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D001341:Autonomic Nervous System / Q000378:metabolism / Q000503:physiopathology; D003327:Coronary Disease / Q000150:complications; D004361:Drug Tolerance; D004910:Erythrocyte Membrane / Q000187:drug effects; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000150:complications; D008297:Male; D008875:Middle Aged; D013015:Sotalol / Q000008:administration & dosage / Q000493:pharmacokinetics; D013318:Stroke Volume / Q000187:drug effects
chemical_list: D000319:Adrenergic beta-Antagonists; D013015:Sotalol